Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors
Appointment of Independent Director Nominee to become effective upon approval by and listing of common stock on a National Exchange
Boca Raton, FL, Jan. 08, 2024 (GLOBE NEWSWIRE) — Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for degenerative eye diseases today announced its nomination to its Board of Directors of Dr. Theresa Heah. Dr. Heah is expected to join its Board of Directors as an independent director upon approval by and listing of the Company’s common stock on a National Exchange. In addition to other Board duties Dr. Heah will serve on the newly created Clinical Development Committee of the Board.